HC Wainwright Has Optimistic Outlook of TRDA Q1 Earnings

Entrada Therapeutics, Inc. (NASDAQ:TRDA) – Equities researchers at HC Wainwright lifted their Q1 2026 earnings per share estimates for shares of Entrada Therapeutics in a research report issued on Monday, March 2nd. HC Wainwright analyst R. Selvaraju now expects that the company will post earnings per share of ($1.12) for the quarter, up from their previous estimate of ($1.20). HC Wainwright currently has a “Buy” rating and a $20.00 target price on the stock. The consensus estimate for Entrada Therapeutics’ current full-year earnings is $1.12 per share. HC Wainwright also issued estimates for Entrada Therapeutics’ Q2 2026 earnings at ($1.30) EPS, Q3 2026 earnings at ($1.12) EPS, Q4 2026 earnings at ($0.96) EPS, FY2026 earnings at ($4.49) EPS, Q1 2027 earnings at ($0.80) EPS, Q2 2027 earnings at ($0.72) EPS, Q3 2027 earnings at ($0.79) EPS, Q4 2027 earnings at ($0.87) EPS and FY2027 earnings at ($3.18) EPS.

Entrada Therapeutics (NASDAQ:TRDA) last announced its quarterly earnings data on Thursday, February 26th. The company reported ($0.94) earnings per share (EPS) for the quarter, topping the consensus estimate of ($1.32) by $0.38. The firm had revenue of $1.30 million for the quarter, compared to analysts’ expectations of $7.41 million. Entrada Therapeutics had a negative return on equity of 39.83% and a negative net margin of 565.48%.

Other research analysts have also issued reports about the stock. Guggenheim raised shares of Entrada Therapeutics to a “strong-buy” rating in a report on Wednesday, February 11th. Weiss Ratings reissued a “sell (d)” rating on shares of Entrada Therapeutics in a report on Monday, December 29th. Oppenheimer assumed coverage on Entrada Therapeutics in a report on Wednesday, January 28th. They set an “outperform” rating and a $21.00 target price for the company. Roth Mkm set a $13.00 price target on Entrada Therapeutics in a research report on Thursday, November 6th. Finally, Wall Street Zen upgraded Entrada Therapeutics from a “sell” rating to a “hold” rating in a research note on Saturday, February 28th. One analyst has rated the stock with a Strong Buy rating, two have given a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and an average target price of $18.50.

Entrada Therapeutics Price Performance

TRDA stock opened at $11.62 on Thursday. The firm has a market cap of $444.81 million, a price-to-earnings ratio of -3.36 and a beta of -0.12. Entrada Therapeutics has a 1-year low of $4.93 and a 1-year high of $12.93. The firm has a fifty day moving average price of $11.01 and a two-hundred day moving average price of $8.64.

Institutional Inflows and Outflows

A number of large investors have recently modified their holdings of the business. Allspring Global Investments Holdings LLC grew its holdings in Entrada Therapeutics by 9.8% during the fourth quarter. Allspring Global Investments Holdings LLC now owns 17,495 shares of the company’s stock worth $176,000 after acquiring an additional 1,560 shares during the period. Alliancebernstein L.P. grew its stake in shares of Entrada Therapeutics by 7.1% in the 3rd quarter. Alliancebernstein L.P. now owns 24,320 shares of the company’s stock worth $141,000 after purchasing an additional 1,620 shares during the last quarter. Great Lakes Advisors LLC raised its holdings in shares of Entrada Therapeutics by 5.5% in the 4th quarter. Great Lakes Advisors LLC now owns 43,268 shares of the company’s stock worth $445,000 after purchasing an additional 2,239 shares in the last quarter. Intech Investment Management LLC raised its holdings in shares of Entrada Therapeutics by 15.7% in the 2nd quarter. Intech Investment Management LLC now owns 17,702 shares of the company’s stock worth $119,000 after purchasing an additional 2,397 shares in the last quarter. Finally, Quadrature Capital Ltd lifted its stake in Entrada Therapeutics by 13.5% during the fourth quarter. Quadrature Capital Ltd now owns 20,318 shares of the company’s stock valued at $209,000 after purchasing an additional 2,424 shares during the last quarter. 86.39% of the stock is owned by institutional investors and hedge funds.

Entrada Therapeutics News Summary

Here are the key news stories impacting Entrada Therapeutics this week:

• Positive Sentiment: HC Wainwright reaffirmed a Buy rating and maintained a $20 price target, which provides upside support despite the estimate cuts. MarketBeat TRDA
• Neutral Sentiment: HC Wainwright nudged its Q1 2026 EPS estimate slightly less negative (from -$1.20 to -$1.12), a small improvement in the near-term outlook that is unlikely to materially change fundamentals.
• Neutral Sentiment: Reported short interest shows 0 shares and a 0.0 days-to-cover figure; the report includes NaN values and looks unreliable, so it should not be treated as meaningful short-pressure evidence.
• Negative Sentiment: HC Wainwright cut multiple 2026 quarterly and full-year EPS forecasts (Q2 2026 to -$1.30 from -$1.24; Q3 2026 to -$1.12 from -$0.98; Q4 2026 to -$0.96 from -$0.81; FY2026 to -$4.49 from -$4.21), increasing near-term expected losses — a likely catalyst for downside pressure on the stock.
• Negative Sentiment: The firm also projects FY2027 EPS of -$3.18 and trimmed some 2027 quarterly expectations, keeping the multi-quarter loss profile intact; these larger negative earnings revisions weigh on investor sentiment despite the Buy rating.

About Entrada Therapeutics

Entrada Therapeutics (NASDAQ: TRDA) is a clinical-stage biotechnology company focused on enabling the development of protein-based therapeutics that can cross cell membranes and engage intracellular targets. Using its proprietary cell-penetrating miniature protein (CPMP) platform and intracellular targeting of proteins (iTOP) delivery technology, Entrada aims to expand the range of diseases addressable by large-molecule drugs.

The company’s pipeline includes programs in rare and serious diseases where conventional biologics have limited intracellular activity.